The Sage Group Advises Cancer Prevention Pharmaceuticals on Transaction for Orphan Drug
New York and London, July 28, 2021 - The Sage Group has announced that it advised Cancer Prevention Pharmaceuticals, Inc. (CPP),...
top of page
Sage Group News
Sage Represents medac GmbH in Deal for Commercialisation Agreement for Treosulfan in Canada
Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada...
The Sage Group Represents VAL401 - A Unique Formulation of Respiridone for Cancer Supportive Care
The Sage Group is working with UK-based ValiRx, which is developing a unique, patented, cancer supportive care product, VAL401, for which...
IPSC-Derived Cardiomyocyte Product to Treat Chronic Heart Failure Patients - Partnering Opportunity
Help Stem Cell Innovations (“HelpTx” or the “Company”; helptx.com.cn) is a Nanjing, China-based stem cell biotechnology company dedicated...
Exhalation Technology Announces Plans for Commercial Launch and Clinical Update on CoronaCheck
Exhalation Technology Announces Plans for Commercial Launch and Clinical Update on CoronaCheck – A Rapid (<5 minutes) Covid-19 Diagnostic...
Zhimeng Biopharma Announces Global Partner Search for its' Development of Chronic Hepatitis B Cure
Shanghai, China and New York, USA, 1 March 2021 – Following a strategic review of its clinical and commercial development options,...
The Sage Group Announces $100M+ Transaction between medac GmbH and Medexus Pharma for Trecondi
The Sage Group Inc. served as exclusive advisor to medac GmbH on this $100M+ transaction. Medexus Pharmaceuticals and medac GmbH enter...
Squarex Announces End of Phase 2 Meeting with FDA for its Cold Sore Prevention Asset
Saint Paul, Minnesota, USA, 19 January 2021 – Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results...
bottom of page